PCA3 and posterior cortical atrophy: Prostate cancer antigen 3 (PCA3), as one of the LncRNAs, has been proven to be a diagnostic marker to improve the diagnostic efficacy of PSA in PCa and has been approved by the FDA to guide repeated prostate biopsy (23, 24).